308 results about "Urinary Bladder Cancer" patented technology

The invention discloses a method for carrying out gene editing and expression regulation by utilizing a Cas splitting system. A protein group is provided for splitting a Cas9 protein amino acid sequence from different sites to form two-section proteins which form a protein group. Proved by an experiment, an Intein-mediated Ca9 splitting system can efficiently realize gene editing and transcriptional activation regulation on a gene circuit. According to the method disclosed by the invention, the CaS9 splitting system is combined with a tumor cell specific promoter, so that specific detection can be carried out on bladder cancer cells.

The invention relates to a method used for detecting whether a detected object suffers from bladder cancer, comprising the following steps: (a) the detected object provides a urinary sediment sample; (b) the methylation spectrum formula of a specific sequence (named as a gene in the following) in one or a plurality of gene promoter areas CpG in the sample is measured; and (c) the methylation spectrum formula of the detected object is compared with that of a normal object, if one or a plurality of genes are in high methylation state, the detected object is proved to suffer from the bladder cancer. The invention also provides a set of kit used for diagnosing the bladder cancer.

The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and / or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.

A method for treating an individual suffering from one of bladder cancer and colorectal cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. Still other embodiments include increasing the levels of Roseburia and / or Faecalibacterium prausnitzii, in the individual's gut microbiome.

This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.

The invention provides application of target up-regulation PAR-4 gene small ribonucleic acid (RNA) in preparing bladder cancer resisting drugs. The nucleotide sequence of the target up-regulation PAR-4 gene small RNA is composed of six positive sense strands and negative sense strands of 21 nucleotides. The 3' end of each strand is provided with two nucleotides in suspension mode (generally dTdT, and the 19 nucleotides in the middle are paired.). The target up-regulation PAR-4 gene small RNA comprises sa RNA of different sequences. By means of expression of target up-regulation PAR-4 genes in the bladder cancer cells, the small RNA can restrain tumor cell activity, induces cell apoptosis, and further can be applied to preparation of bladder cancer resisting drugs. The application of target up-regulation PAR-4 gene small RNA in preparing the bladder cancer resisting drugs is simple in operation of preparing the small RNA, low in cost, small in using amount, capable of achieving good activation effect when the transfection concentration is 50nM and accurate in activation action. The mRNA and protein level of the target genes are both improved. In addition, the sa RNA can induce genes to express without damaging completeness of gene groups, thereby being safe to use.